Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary XXXX .

@entity1 @entity172 @entity3525 @entity137 @entity0 @entity1261 @entity1259 @entity33 @entity2033 @entity2280 @entity1487
The feasibility and safety of the administration of multiple cycles of dose-intensive chemotherapy (CT) supported with repeated reinfusions of circulating progenitor cells (CPCs) were evaluated in a prospective study of adjuvant initial therapy of poor-prognosis @entity0 . Eighteen @entity1 with resectable @entity0 involving >/= 10 axillary nodes or >/= 5 axillary nodes and negativity of the @entity172 receptor status received a cycle of standard FEC regimen (5-FU 600 mg/m2, @entity1259 60 mg/m2, @entity3525 600 mg/m2, i.v. on day 1) followed by @entity1261 as CPC mobilization technique. Collected CPCs were fractionated and reinfused, with @entity1261 , after each of the 4 subsequent cycles of high-dose FEC ( @entity2033 -FEC) ( @entity1487 750 mg/m2, @entity1259 120 mg/m2, @entity3525 3 g/m2, i.v.) planned at 21 day intervals. The median numbers of @entity2280 + cells and CFU-GM collected (with one or two leukaphereses per @entity1 ) were 9.7x10(6)/kg (range: 2.5-22.9) and 9.9x10(4)/kg (range: 1.9-27.3), respectively, and day 9 was the median first day of procedure (range: 8-12) after FEC. All @entity1 received the 4 courses of @entity2033 -FEC (for a total of 72 cycles). Hemopoietic recovery was rapid after each cycle and there was no treatment-related delays in CT administration. @entity33 was the major non-hematological @entity137 . There were 2, 3, 7 and 9 episodes of WHO grade 3/4 @entity33 in cycles 1, 2, 3 and 4, respectively. These severe episodes lasted a median of 4 days (range: 2-6) but no @entity1 required parenteral nutrition. The mean +/- SD total hospital stay lasted 10 +/- 2 days. The delivery of 4 cycles of dose-intensive FEC CT supported by CPCs (mobilized with a single course of standard-dose FEC + @entity1261 ) is feasible and safe. It could represent an effective alternative strategy to other more aggressive programs for the adjuvant therapy of high-risk early @entity0 .
